BPC-157 + TB-500 Blend
Also referenced as: BPC/TB, BPC-157 with TB-500 10/10 mg
A combination research vial pairing two peptides studied in animal models of tissue repair, commonly supplied as 10 mg of each.
- Evidence grade
- DPreclinical Research
Preclinical Research
- Regulatory status
- Research Use Only
Neither component is an approved medicine. BPC-157 is prohibited in sport under the World Anti-Doping Agency code. Sold as research-use-only material.
- Human data
- No
No registered clinical trials identified
- Last reviewed
- September 14, 2026
Overview
This blend combines BPC-157, a synthetic pentadecapeptide studied in gastrointestinal and soft-tissue injury models, with TB-500, a fragment related to thymosin beta-4 studied in cell migration and wound models.
The rationale offered is complementary repair pathways: angiogenic and cytoprotective signalling from one, actin-regulated cell migration from the other. This is a mechanistic argument, not a trial result.
Commonly supplied for research as a single vial containing 10 mg of each compound. No published human study has evaluated the combination.
Why It's Being Studied
- Tendon, ligament and muscle repair in animal injury models.
- Angiogenesis and granulation tissue formation.
- Cell migration and cytoskeletal remodelling during wound closure.
Mechanism of Action
Both peptides are studied for helping damaged tissue heal in animals, through different routes: new blood vessels and cell movement into the wound.
BPC-157 has been reported to upregulate VEGF-A and eNOS signalling, modulate the FAK-paxillin pathway and interact with nitric oxide systems in rodent injury models. TB-500 corresponds to the actin-binding region of thymosin beta-4, sequestering actin monomers and promoting cell migration, with reported effects on laminin-5 and endothelial differentiation. Neither pathway has been characterised in controlled human injury studies.
Research Areas & Routes Studied
- Tendon and ligament repair
- Muscle injury
- Gastrointestinal mucosal healing
- Wound closure
- Subcutaneous injection (animal and research use)
- Intramuscular injection (research)
Evidence Summary
Both components are supported only by animal and laboratory research for tissue repair, and the combination itself has never been studied in humans.
Human clinical evidence
- No controlled human trials of the combination, or of BPC-157 and TB-500 for tissue repair, have been identified.
Animal studies
- Rodent studies report accelerated healing of tendon, muscle, ligament and gastrointestinal lesions with BPC-157.
- Thymosin beta-4 and its active fragment promote cell migration and wound closure in animal and cell models.
Anecdotal / community information
- Injury-recovery reports from athletes and community users dominate the available information and are uncontrolled.
Reported Adverse Events in Research
- No systematic human safety data exist for either component or the blend.
- Injection-site reactions, and infection or contamination risk from research-use-only material.
- Theoretical concern about promoting growth of existing abnormal tissue, given angiogenic mechanisms.
Limitations of Current Evidence
- Animal healing models translate poorly to human tendon and ligament outcomes.
- No human pharmacokinetic data, so exposure after injection is unknown.
- Blended vials prevent independent adjustment or attribution of effects.
- BPC-157 is prohibited in sport, which matters for any tested athlete.
Why It Is Used
- Recovery
Soft-Tissue Injury and Recovery
BPC-157 is the single most searched research peptide. The gap between how confidently it is discussed and what has been published in humans is the story here.
Read the case study
Research References
- Animal study
BPC-157 in tendon and muscle healing: animal studies
- Narrative review
Thymosin beta-4 and tissue repair
- Regulatory document
WADA Prohibited List